Savannah Book Festival: author Dr. Daniel J. Levitin
Dr. Daniel Levitin, a renowned cognitive psychiatrist, has written a book, I Heard There Was A Secret Chord, exploring the curative powers of music, showing us how and why it is one of the most potent therapies today. He brings together, for the first time, the results of numerous studies on music and the brain, demonstrating how music can contribute to the treatment of a host of ailments, from neurodegenerative diseases such as Parkinson's and Alzheimer's, to cognitive injury, depression, and pain. And he will be at the 2025 Savannah Book Festival to discuss his findings.
So to begin with, why do we like some music and not other kinds? Dr. Levitin says it's not that cut and dried. 'There's not good music and bad music. There's music I like and music I don't care for. And maybe someday I'll care for it. Maybe I never will. But I retain an open mind. Musical preferences is an area of active research in my field. Why do people like the music they like? And it's complicated.'
Complicated because there are so many factors. 'There are genetic instructions for things like a propensity to be open-minded and curious that will go a long way in terms of musical taste. Some people are genetically predisposed to say, 'I don't want to hear that.' Others will say, 'Wow, that's new and shiny and interesting. Let me explore that.'
Dr. Levitin says environment also plays a part in musical preference. 'Whether you're rebelling, or a conformist, we tend to listen to music that our friends are listening to or what the people we care about are listening to.'
As a scientist, Dr. Levitin is very qualified to discuss the many ways music impacts our lives. But he is also a talented musician himself. He plays piano, clarinet, saxophone, and guitar. He also writes music and songs. He has worked with some of the biggest music acts, producing and engineering their work. When asked who he listens to, he said, 'Well, you know, most of my friends are songwriters, and so I get a constant stream of stuff they're working on. A lot of it [hasn't been] released yet.'
Levitan is always on the hunt for something new too. 'It goes back to my days in the eighties when I was a talent scout for Columbia Records, and I would get mail bins full of stuff every day that nobody had ever heard. And I still listen to some of it.'
Levitin is excited to come to the Savannah Book Festival for the first time to promote his latest book. 'I'm looking forward to presenting the book to this esteemed and celebrated festival.' His session will feature something different than others: he'll be joined on stage by Howard Paul, president and CEO of Benedetto Guitars, the premier jazz guitars made right here in Savannah. They've known each other for years. Paul will play one of his favorite Benedettos during Levitin's session as an example of how music impacts us.
Levitin is also participating in the Festival's 'SBF@Schools' program, where authors go into local schools. They discuss their writing process and answer questions from students. He's scheduled to participate in an American Literature class at Herschel V. Jenkins High School the day before Free Festival Saturday.
'With any scientist in any field, when we find something that doesn't make sense, we love that. It means there's some knowledge in the canon that's missing.' Levitin's I Heard There Was a Secret Chord brings together dazzling ideas, cutting-edge research, and a love of all things music.
For more on Dr. Daniel Levitin's Savannah Book Festival appearance, go to savannahbookfestival.org.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
a few seconds ago
- Newsweek
Alzheimer's: Omega-3 Fatty Acids May Protect Women From Disease
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Omega-3 fatty acids could help to protect women against Alzheimer's—with women "disproportionately impacted" by the disease compared to men. It seems there is a noticeable loss of unsaturated fats, like those that contain omega fatty acids, in the blood of women with Alzheimer's disease compared to healthy women. Scientists from King's College London came to this discovery through analysis of lipids—fat molecules that perform many essential functions in the body. They found no significant difference in the same lipid molecule composition in men with Alzheimer's disease compared to healthy men. This suggests—for the first time—that those lipids have a different role in the disease dependent on sex, according to the researchers. Close up of woman holding a plate with avocado and salmon toast. Close up of woman holding a plate with avocado and salmon perform important roles in maintaining a healthy brain, with Omega-3 fatty acids particularly known for their benefits to brain function and heart health, hence why the study could point to the reason more women are diagnosed with the disease. "Women are disproportionately impacted by Alzheimer's disease and are more often diagnosed with the disease than men after the age of 80," said study author and biochemist Cristina Legido-Quigley in a statement. "One of the most surprising things we saw when looking at the different sexes was that there was no difference in these lipids in healthy and cognitively impaired men, but for women this picture was completely different. "The study reveals that Alzheimer's lipid biology is different between the sexes, opening new avenues for research." Almost two-thirds of Americans living with Alzheimer's disease are women, according to the Alzheimer's Association. Women in their 60s are more than twice as likely to develop Alzheimer's over the rest of their lives as they are to develop breast cancer. Not only are they more affected than men from the disease itself, but more than 60 percent of Alzheimer's and dementia caregivers are women. In the study, the scientists took plasma samples from 841 participants who had Alzheimer's disease, mild cognitive impairment and cognitively healthy controls. They were measured for brain inflammation and damage. They used an analytical tool called mass spectrometry to analyze the 700 individual lipids in the blood. Saturated lipids are generally considered 'unhealthy' or 'bad', while unsaturated lipids—of which can contain omega fatty acids—are generally considered 'healthy'. The scientists reported a steep increase in lipids with saturation in women with Alzheimer's compared to the healthy group. The lipids with attached omega fatty acids were the most decreased in the Alzheimer's group. There appears to be a statistical indication that there is a "causal link" between Alzheimer's disease and fatty acids, the scientists said, though a clinical trial is needed to confirm this. "Our study suggests that women should make sure they are getting omega fatty acids in their diet—through fatty fish or via supplements. However, we need clinical trials to determine if shifting the lipid composition can influence the biological trajectory of Alzheimer's Disease," Legido-Quigley added. Behind shot of young female carer walking with the elderly woman in the park. Behind shot of young female carer walking with the elderly woman in the park. Obencem/Getty Images "Women have higher levels of lipids with omega-3 fatty acids than men normally, so when these become depleted—our study shows up to 20 percent decrease in women with Alzheimer's disease—this could be important for the health of their brains. A surprising fact is that a healthy brain is mostly made up of fats," Legido-Quigley told Newsweek. "The lipid associations with Alzheimer's disease were predominantly driven by female participants with no individual lipid associations detected in men. The observation is that men do not share the same biology but it is difficult to pin where this is happening in the body." While Legido-Quigley confirmed the study suggests the possibility that Alzheimer's rates in women could be lowered through diet, she added that more research is needed to establish prevention protocols—ideally a clinical trial. The types of treatment methods it could lead to include "repurposing drugs that target lipid metabolism pathways" and potentially "looking into hormone replacement therapy." "But we need to study that in detail and see if women at midlife already experience this lipid biology," Legido-Quigley added. Julia Dudley, Head of Research at Alzheimer's Research UK said in a statement that the rate of women living with dementia could be linked to living longer, or other risk factors like social isolation, education or hormonal changes from the menopause being at play. "While this study shows that women with Alzheimer's had lower levels of some unsaturated fats compared with men, further work is needed," Dudley added. This includes understanding the mechanisms behind this difference and finding out if lifestyle changes, including diet, could have a role. Future research should also be carried out in a more ethnically diverse population to see if the same effect is seen." "Understanding how the disease works differently in women could help doctors tailor future treatments and health advice." Do you have a tip on a health story that Newsweek should be covering? Do you have a question about Alzheimer's? Let us know via health@
Yahoo
9 hours ago
- Yahoo
Breakthrough study finds deficiency of this common nutrient could contribute to Alzheimer's
A deficiency of the metal lithium in the body could be a key factor contributing to the development of dementia in Alzherimer's patients, a groundbreaking new study reveals. The decade-long research, published in the journal Nature, shows for the first time that lithium occurs naturally in the brain and maintains the normal function of all its major cell types, preventing nerves from degradation. Scientists from Harvard Medical School found that lithium loss in the human brain is one of the earliest changes leading to Alzheimer's, while in mice, a similar lithium depletion accelerated memory decline. A reduced lithium level was found in some cases due to the metal's impaired uptake and its binding to amyloid plaques, which are known to be smoking gun signs of Alzheimer's. Researchers also showed that a new type of lithium compound – lithium orotate – can avoid capture by amyloid plaques and restore memory in mice. In the study, scientists used an advanced type of mass spectroscopy chemical analysis method to measure trace levels of about 30 different metals in the brain and blood samples from a range of people, including cognitively healthy people, those in an early stage of dementia, and those with advanced Alzheimer's. The analysis revealed that lithium was the only metal with markedly different levels across groups, which also seemed to change at the earliest stages of memory loss. 'Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,' study senior author Bruce Yankner said. 'It's the first time anyone's shown that lithium exists at a natural level that's biologically meaningful without giving it as a drug,' Dr Yankner said. Although lithium compounds have been historically in use to treat a range of mental conditions like bipolar disorder and major depressive disorder, in these cases, they are given at much higher concentrations that could even be toxic to older people. Scientists have now found that lithium orotate is effective at one-thousandth this dose – enough to mimic the natural level of lithium in the brain. The latest findings with lithium orotate, however, needs to be confirmed in humans via clinical trials. Yet, researchers suspect that measuring lithium levels could help screen people for early Alzheimer's. The findings revise the theory of Alzheimer's disease, which affects nearly 400 million people worldwide, offering a new strategy for early diagnosis, prevention, and treatment. Decades of studies have shown that Alzheimer's disease involves an array of brain abnormalities, including clumps of the protein amyloid beta, tangles of the protein tau, and a loss of the brain's protective protein REST. However, these abnormalities have never fully explained the condition. For instance, it remains unclear why some people with Alzheimer's-like changes in the brain never go on to develop dementia or cognitive decline. Recent treatments developed to target amyloid beta plaques also don't seem to reverse memory loss, only modestly reducing the rate of cognitive decline. Now, scientists say lithium could be the critical missing link. 'The idea that lithium deficiency could be a cause of Alzheimer's disease is new and suggests a different therapeutic approach,' Dr Yankner said. 'You have to be careful about extrapolating from mouse models, and you never know until you try it in a controlled human clinical trial... But so far the results are very encouraging,' he added. Solve the daily Crossword
Atlantic
13 hours ago
- Atlantic
The Future of Alzheimer's Diagnosis Is Now
A patient enters her general practitioner's office for a routine checkup. She is 65 years old, and—knock on wood—in good health: walking outside every morning, eating a thoughtful diet, and reading voraciously. All of this she naturally tells her doctor during the visit. However, lately she's been forgetting things here and there. Nothing major, she thinks. It's just a normal part of getting older. So this small detail she keeps to herself. But by holding on to that detail, the patient is also putting off a conversation that could change the course of her life as well as her family's. Memory change is not always a part of normal aging, with more than 7 million adults living with Alzheimer's disease in the United States—a number that is expected to almost double in the next few decades. The fear that talking about it will lead to a road of invasive procedures, life-changing diagnoses, and painful choices is all too common. However, new scientific developments in diagnostics have been made so medical experts can help diagnose or rule out Alzheimer's disease sooner, and more easily, than ever before with a simple blood test. In this new era, patients can rule out the disease as a diagnosis or talk to their doctors about care options and plan with their families if they receive a diagnosis. When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future Brandy Matthews Vice President of Global and U.S. Medical Affairs for Eli Lilly and Company 'We have to overcome this barrier of stigma,' says Brandy Matthews, M.D., FAAN, vice president of global and U.S. medical affairs for Alzheimer's disease at Eli Lilly and Company, 'and then the reinforcement of the myths [so] that people will raise their hand when they begin to experience changes in their memory and thinking.' In addition to the laboratory developed tests that are already available and developed under the Clinical Laboratory Improvement Amendments (CLIA) to aid in Alzheimer's disease diagnosis, the FDA recently cleared the first in vitro diagnostic (IVD) blood biomarker test. These tests can be administered to symptomatic patients as part of a cognitive workup. 'The fact that there's been a recent FDA clearance for a blood biomarker in Alzheimer's disease is really critical and really big and I think will be a sort of a monumental shift in how we diagnose Alzheimer's disease,' says Anthony 'Nino' Sireci, M.D., MSc, senior vice president of clinical biomarkers, laboratories and diagnostics at Eli Lilly and Company. The work of developing new technology to diagnose a disease is painstaking and slow, but these breakthroughs are essential for patients. These advances not only offer hope to millions but also provide researchers like Matthews and Sireci with a profound sense of purpose. 'When patients receive a timely and accurate diagnosis, this opens up the opportunity for them to make plans for the future, to engage in lifestyle modifications, and to explore options for therapies that may target their symptoms or the underlying pathology of the disease,' says Matthews. Way back in 1906, the German neuropathologist Alois Alzheimer identified what he called 'an unusual disease of the cerebral cortex' marked by symptoms of memory loss. Using newly available technology, he identified two key pathological proteins in the neurons of his patients' brain cells: Beta-amyloid and tau. Beta-amyloid and tau are proteins produced naturally in the body. In patients with Alzheimer's disease, beta-amyloid starts to clump together, creating plaques between brain cells, while tau twists together into tangles inside brain cells. 'They are involved in a cascade of changes that happen in the brain, presumably initially with amyloid plaque accumulation, followed by tau tangle accumulation, leading to the dysfunction of the brain cells and then eventually neurodegeneration or shrinking of the brain. That results in the symptoms of Alzheimer's disease,' says Matthews. To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly Beta-amyloid plaques and tau tangles are the cause of the disease, but for nearly a century following their initial discovery, they could be identified only posthumously. This changed in 2002, when scientists identified amyloid plaque in the brain of a patient with a PET scan for the first time, using an imaging agent approved by the FDA in 2012. In 2022, the FDA cleared its first biomarker test measuring the presence of beta-amyloid in cerebrospinal fluid (CSF), drawn during a lumbar puncture (also known as a spinal tap). 'Modified fragments of those proteins are released into the cerebrospinal fluid,' says Sireci. 'And so those become some of the biomarkers that you measure in CSF.' While effective tools and necessary parts of the diagnostic process, PET scans and spinal taps are invasive and not always readily available, depending on where patients are located. This is where blood biomarkers come in, because beta-amyloid and tau aren't released only into CSF. 'Some of them actually leak out into the blood in super small quantities,' says Sireci. 'And that's what we use as the basis for identification of blood biomarkers in patients with Alzheimer's disease.' The traces found in these tests are smaller and harder to identify than the ones found in CSF. One challenge has been innovating over years to make blood test more closely resemble CSF – a major breakthrough developed over years of challenging work. And such tests require patients access and provider experience. In an ideal world, a simple blood sample could be collected at any doctor's office, even in rural or underserved communities, and sent to a major reference lab where, combined with the patient's initial cognitive assessment, it could provide information to help the treating physician to diagnose Alzheimer's disease without the need for additional confirmatory testing. That would vastly expand access to timely diagnosis. But there is still a lot of work to do between the clearance of a medical technology and its implementation. 'The obstacles now are not scientific,' says Sireci. 'Medicine is a logistical effort.' Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big. Anthony 'Nino' Sireci, M.D. Senior Vice President of Diagnostics Development at Lilly 'It's implementation,' he says. 'Are the [diagnostic] assay themselves robust enough that physicians feel confident in the results and confident in how they interpret them? That's really big.' But with any new diagnostic tools come questions. Are physicians educated in how to understand the results? Are they confident in those results? And once they are, are they actually able to order the test at scale from high quality labs? It's about quality and it's about access. And that's only on the medical side. What about patients? Will insurers reimburse the tests so that patients are not faced with high out-of-pocket costs? Will patients embrace them? Sireci is optimistic about both possibilities. A recent survey by the Alzheimer's Association found that 91 percent of patients would want a blood biomarker test if it were made available to them. A readily available blood biomarker test gives doctors and patients a tool to aid in accurate and timely diagnosis. That patient who walked into her general practitioner's office? She would undergo a routine cognitive exam (a recommended standard for all patients 65 and older). She would have an honest conversation with her doctor about changes she might be perceiving in her brain function, however slight. And if the doctor thought it was necessary, a referral to a specialist for a simple blood test would be administered to help inform next steps. Then, unlike in the decades when Alzheimer's disease could be diagnosed only symptomatically or after an invasive procedure, the doctor would lead her in an informed, fact-based discussion—right away. From that conversation, the patient could undergo a PET scan or CSF testing to confirm or rule out the diagnosis if necessary. 'To be able to have a data-driven conversation, I think, is going to be pretty big in ensuring, number one, that patients are appropriately triaged,' says Sireci, 'but also [that] they're not waiting years for a diagnosis, which unfortunately is what's happening today.' We're moving the needle for patients and giving physicians another very powerful tool to combat this disease. Anthony 'Nino' Sireci M.D., Senior Vice President of Diagnostics Development at Lilly This is crucial because Alzheimer's is a progressive disease. Timing is critical. The earlier a patient is diagnosed, the more time they have for planning, which could include treatment options a patient has available to them. They can set themselves up for counseling, talk to their families, and could choose to begin medical intervention. 'We've learned over time that initiating therapy in the earlier stages of disease can have greater impact,' says Matthews. 'And even within those early symptomatic stages of disease, there's evidence, across a class of medicines, that the earliest stages of early symptomatic Alzheimer's disease may demonstrate the greatest benefit of new therapies.' For Sireci, who has experience with Alzheimer's disease both as a doctor and as the family member of a patient, the most gratifying aspect of his research is knowing that it can help shorten what he calls the 'diagnostic odyssey.' 'Even if that just means getting the conversation to happen for the physician faster than it would've, then I'm happy,' says Sireci. 'That's a really big deal. We're moving the needle for patients and giving physicians another very powerful tool to combat this disease.' The Future of Alzheimer's Diagnosis Is Now Hear more from Brandy Matthews, Vice President of Global and U.S. Medical Affairs at Eli Lilly and Company, on the future of Alzheimer's diagnosis. learn more
